Equity · Healthcare
JAZZ
NASDAQJazz Pharmaceuticals (JAZZ)
The line runs 254 USD on 24 August through 230.57 USD on 20 November, on a scale from 200 to 280. Days the market did not trade hold the previous close, flat.
- Market cap
- 14.8B USD
- P/E (TTM)
- 75.1
- Revenue, year to Dec 2025
- 4.3B USD
- EPS, diluted, year to Dec 2025
- −5.84 USD
- 52-week range
- 141 USD – 262 USD
- Avg volume
- 55.8K
- Mentions, 30 days
- 16
- Net sentiment
- +0.01
as of Nov 20, 2026
Have Jazz Pharmaceuticals (JAZZ) insiders bought or sold shares recently?
In the 90 days to 23 Nov 2026, Jazz Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 26 Feb 2026, show no open-market purchase.
Form 4, 90 days to 23 Nov 2026, newest reported trade 6 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 06 Nov 2026 | COZADD BRUCE CDirector | Sell | 68,808 | 16.2M USD |
| 04 Nov 2026 | Carr PatriciaSVP, Chief Accounting Officer | Sell | 1,413 | 327K USD |
| 03 Nov 2026 | GALA RENEE DPresident & CEO | Sell | 1,000 | 225K USD |
| 02 Nov 2026 | COZADD BRUCE CDirector | Sell | 6,000 | 1.3M USD |
| 06 Oct 2026 | GALA RENEE DPresident & CEO | Sell | 2,000 | 473K USD |
| 01 Oct 2026 | COZADD BRUCE CDirector | Sell | 6,000 | 1.4M USD |
| 10 Sep 2026 | Patil Neena MEVP & Chief Legal Officer | Sell | 1,200 | 289K USD |
| 08 Sep 2026 | GALA RENEE DPresident & CEO | Sell | 2,000 | 486K USD |
| 01 Sep 2026 | COZADD BRUCE CDirector | Sell | 6,000 | 1.5M USD |
| 27 Aug 2026 | Iannone RobertEVP, Global Head of R&D & CMO | Sell | 76,921 | 19.2M USD |
| Sold | 10 open-market sales | 171,342 | $41.42M |
16 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 06 Nov 2026 | COZADD BRUCE CDirector | Option exercise | 86,500 | 11.8M USD |
| 04 Nov 2026 | Carr PatriciaSVP, Chief Accounting Officer | Option exercise | 1,250 | 175K USD |
| 08 Sep 2026 | Henderson Mary ElizabethSVP, Technical Operations | Tax withheld | 1,427 | 347K USD |
| 08 Sep 2026 | GALA RENEE DPresident & CEO | Tax withheld | 1,967 | 485K USD |
| 31 Aug 2026 | Kennedy PatrickDirector | Tax withheld | 1,855 | 448K USD |
| 31 Aug 2026 | Henderson Mary ElizabethSVP, Technical Operations | Tax withheld | 2,092 | 505K USD |
| 31 Aug 2026 | Smith Mark DouglasDirector | Tax withheld | 1,706 | 412K USD |
| 31 Aug 2026 | Cook Jennifer E.Director | Tax withheld | 1,706 | 412K USD |
| 31 Aug 2026 | Hamill LauraDirector | Tax withheld | 1,706 | 412K USD |
| 31 Aug 2026 | McSharry Heather AnnDirector | Tax withheld | 1,855 | 448K USD |
| 31 Aug 2026 | Winningham Rick EDirector | Tax withheld | 1,706 | 412K USD |
| 31 Aug 2026 | ENRIGHT PATRICK GDirector | Tax withheld | 1,706 | 412K USD |
Showing the 12 most recent of 16 compensation filings in this window. The figures above count all of them.
Which funds hold Jazz Pharmaceuticals (JAZZ)?
9 of the 45 institutional funds we track reported a Jazz Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 916.6M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Held (±25%) | 1,173,813 | 271.0M USD | −22.9% |
| Citadel Advisors | Held (±25%) | 1,072,736 | 248.4M USD | +6.6% |
| Two Sigma Investments | Added | 702,217 | 162.6M USD | +75.5% |
| Renaissance Technologies | Held (±25%) | 483,573 | 112.0M USD | −14.0% |
| Man Group | Held (±25%) | 166,253 | 38.5M USD | +8.7% |
| Millennium Management | Trimmed | 164,259 | 38.0M USD | −78.5% |
| Bridgewater Associates | New position | 145,155 | 33.6M USD | |
| D. E. Shaw & Co. | Trimmed | 28,600 | 6.6M USD | −67.2% |
| Marshall Wace | Trimmed | 25,517 | 5.9M USD | −26.7% |
| Balyasny Asset Management | Exited |
Have members of Congress traded Jazz Pharmaceuticals (JAZZ)?
The most recent congressional trade disclosed in Jazz Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 12 Jul 2023.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Jul 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 15K USD–50K USD | 32 days |
| 06 Mar 2023 | Daniel S. Goldmanhouse · Democrat–NY | Purchase | 15K USD–50K USD | 42 days |
| 31 Jan 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 1K USD–15K USD | 24 days |
| 19 Oct 2021 | Thomas R. Suozzihouse · Democrat–NY | Purchase | 1K USD–15K USD | 17 days |
What has been filed or recorded for Jazz Pharmaceuticals (JAZZ)?
The filings we hold for Jazz Pharmaceuticals, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 27 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 574 shares | 118K USD notional · 0.001% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,610 shares | 775K USD notional · 0.006% of shares out |
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 199 shares | 43K USD notional · <0.001% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,115 shares | 445K USD notional · 0.003% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 102 shares | 23K USD notional · <0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 6 shares | 1K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −7.48 USD | |
| 30 Sep 2026 | Financials | Total assets | 12.0B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 4.2B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 2.78 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 4.43 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −5.84 USD | |
| 31 Dec 2025 | Financials | Revenue | 4.3B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −356.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −5.84 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 4.08 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −11.74 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.52 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 8.65 USD |
What is Reddit saying about Jazz Pharmaceuticals (JAZZ)?
Reddit mentioned JAZZ 16 times in the 30 days to 22 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 56% read bullish, 19% bearish and 25% neither. Reddit data updated 22 November 2026.
30-day window, Method
How do Reddit mentions of Jazz Pharmaceuticals (JAZZ) compare with its price?
Share ↗
Which subreddits are talking about Jazz Pharmaceuticals (JAZZ)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 63% | 10 | −0.04 |
| r/ausfinance | 38% | 6 | +0.10 |
Which names move with Jazz Pharmaceuticals (JAZZ) on Reddit?
DOLE moved most closely with Jazz Pharmaceuticals (JAZZ): when the crowd talked about one, it talked about the other (+0.69 over 31 days). Co-discussion, not price.
BRY | ||||||
|---|---|---|---|---|---|---|
JAZZ | +0.69 | +0.68 | +0.66 | +0.65 | +0.65 | +0.62 |
View the matrix as a tableHide the table
| Pair | Match | Days measured |
|---|---|---|
| JAZZ and DOLE | +0.69 | 31 days |
| JAZZ and FEAT | +0.68 | 31 days |
| JAZZ and BRY | +0.66 | 31 days |
| JAZZ and SCI | +0.65 | 31 days |
| JAZZ and ESP | +0.65 | 31 days |
| JAZZ and BITS | +0.62 | 31 days |
What do people ask about Jazz Pharmaceuticals (JAZZ)?
What did Jazz Pharmaceuticals shares close at?230.57
Jazz Pharmaceuticals closed at 230.57 USD on 20 Nov 2026, down 2.44% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Jazz Pharmaceuticals’ market cap?14.8B
Jazz Pharmaceuticals is worth 14.8B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Jazz Pharmaceuticals’ P/E ratio?75.1
Jazz Pharmaceuticals has a price-to-earnings ratio of 75.1, as of 20 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Jazz Pharmaceuticals’ revenue?4.3B
Jazz Pharmaceuticals reported revenue of 4.3B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Jazz Pharmaceuticals insiders bought or sold shares recently?10 sales
In the 90 days to 23 Nov 2026, Jazz Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 26 Feb 2026, show no open-market purchase. A further 16 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Jazz Pharmaceuticals?9 of 45
9 of the 45 funds we track reported a Jazz Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Citadel Advisors and Two Sigma Investments. See Funds
Have members of Congress traded Jazz Pharmaceuticals?4 trades
Yes. 4 trades in Jazz Pharmaceuticals appear in the congressional disclosures we hold; the latest is a sale by Daniel S. Goldman (House, NY) dated 12 Jul 2023, filed 13 Aug 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Jazz Pharmaceuticals last report earnings?−7.48
Jazz Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −7.48 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Jazz Pharmaceuticals?0 mentions
Jazz Pharmaceuticals was mentioned 0 times in the last 7 days across the finance subreddits we track, and 16 times over the trailing 30 days. Of the 16 mentions scored for sentiment, 56% read bullish and 19% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Daniel S. Goldman: US House, Public domain; Thomas R. Suozzi: Österreichisches Außenministerium (BMEIA/ Michael Gruber), CC BY 4.0.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words